Three-year outcome for patients with rheumatoid arthritis with persistent moderate disease activity (group 1) and sustained DAS28 remission (group 2) during the first year of follow-up
| Outcome variable | Group 1 (n=107) | Group 2 (n=155) | p Value |
|---|---|---|---|
| mTSS | 16.1±14.9 | 11.2±11.8 | 0.019 |
| ΔmTSS from day 0* | 10.8±6.5 | 6.5±8.9 | 0.006 |
| ΔmTSS≥5†(%) | 56.0 | 39.2 | 0.021 |
| DAS28 remission (%) | 27.4 | 81.0 | <0.0001 |
| SDAI remission (%) | 13.8 | 56.0 | <0.0001 |
| ACR/EULAR remission‡ (%) | 10.3 | 50.4 | <0.0001 |
| HAQ–DI | 0.68±0.61 | 0.21±0.38 | <0.0001 |
| HAQ–DI <0.5 (%) | 43.7% | 80.6 | <0.0001 |
| Missed workdays§ | 157.3±226.2 | 30.9±75.9 | 0.001 |
| Missed workdays=0¶ (%) | 51.4 | 67.7 | 0.007 |
Data are mean±SD unless indicated.
*Change in mTSS from day 0; †change in mTSS≥5 from day 0; ‡Boolean definition; §mean missed workdays since baseline; ¶percentage of patients without any missed workdays during follow-up.
ACR/EULAR, American College of Rheumatology/European League Against Rheumatism; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire-Disability Index; mTSS, van der Heijde modified total Sharp score; SDAI, Simplified Disease Activity Index.